Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
Portfolio Pulse from Vandana Singh
Truveta Research's study shows Eli Lilly's Mounjaro (tirzepatide) is more effective for weight loss than Novo Nordisk's Ozempic (semaglutide) in overweight or obese adults. Mounjaro patients lost significantly more weight over various time frames compared to Ozempic patients, with similar rates of gastrointestinal adverse events. LLY stock is slightly down by 0.10%, while NVO stock is down 1.48% in premarket trading.
November 28, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Mounjaro shows superior weight loss results compared to Novo Nordisk's Ozempic, potentially boosting its market share and revenue in the obesity treatment sector.
The positive results from the Truveta Research study are likely to increase investor confidence in Eli Lilly's Mounjaro, potentially leading to an increase in prescriptions and market share in the competitive diabetes and weight loss medication market. This could translate to higher revenues for Eli Lilly, positively impacting the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
Novo Nordisk's Ozempic is shown to be less effective than Eli Lilly's Mounjaro in a weight loss study, which may negatively affect its market position and sales.
The study's findings that Mounjaro is more effective than Ozempic for weight loss could lead to a decrease in Ozempic's market share and sales as doctors and patients may prefer the more effective treatment. This could have a negative impact on Novo Nordisk's stock price in the short term as the market reacts to the potential shift in competitive advantage.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90